and FGF receptor signaling (7), attenuated pulmonary fibrosis in an animal model of 60 lung fibrosis resembling aspects of IPF (13) . Nintedanib (BIBF1120) and BIBF1000
61
are indolinone derivatives designed during the same chemical lead optimization
62
program and are very similar with respect to the kinase specificity profile (7, 13).
63
Nintedanib has anti-tumor activity and like BIBF1000 anti-fibrotic activity in animal different between BIBF1000-treated and vehicle treated PAB groups (Figure 7A-B) . At the start of our study a dosing rationale was available for BIBF1000 in rats (7) but pertaining to the effects of these TKIs on cardiac adaptation cannot be made. A decrease in RVSP after PAB is most likely explained by growth inhibition, as the 305 pressure gradient over a stenosis with a fixed diameter is determined by blood flow.
306
In the normal and well-adapted heart, cardiac output is strongly related to body 307 weight. In fact, we observed that treatment with 50 mg/kg BIBF1000 hampered body 308 weight gain which also decreased cardiac output, whereas CI was unchanged. This 309 finding indicates that our dosing strategy was sufficiently rigorous, and that the 
